GOLDMAN SACHS GROUP INC - CATALYST PHARMACEUTICALS INC ownership

CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 138 filers reported holding CATALYST PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.04 and the average weighting 0.1%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of CATALYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$11,319,649
-32.6%
968,319
-22.6%
0.00%
-33.3%
Q2 2023$16,807,097
-10.8%
1,250,528
+10.0%
0.00%
-25.0%
Q1 2023$18,847,099
+32.6%
1,136,737
+48.8%
0.00%
+33.3%
Q4 2022$14,209,712
+53.8%
763,963
+6.1%
0.00%
+50.0%
Q3 2022$9,240,000
-31.0%
720,126
-62.3%
0.00%
-33.3%
Q2 2022$13,394,000
+46.4%
1,910,664
+73.2%
0.00%
+50.0%
Q1 2022$9,147,000
+87.2%
1,103,361
+52.8%
0.00%
+100.0%
Q4 2021$4,887,000
+29.0%
721,926
+1.0%
0.00%0.0%
Q3 2021$3,789,000
-38.3%
714,857
-33.1%
0.00%0.0%
Q2 2021$6,142,000
-6.3%
1,068,147
-24.9%
0.00%
-50.0%
Q1 2021$6,556,000
-39.1%
1,421,993
-55.9%
0.00%
-33.3%
Q4 2020$10,763,000
+43.2%
3,222,590
+27.3%
0.00%
+50.0%
Q3 2020$7,518,000
-21.4%
2,531,488
+22.3%
0.00%
-33.3%
Q2 2020$9,564,000
+26.5%
2,070,240
+5.4%
0.00%0.0%
Q1 2020$7,563,000
+4.7%
1,964,464
+1.9%
0.00%
+50.0%
Q4 2019$7,226,000
+40.6%
1,926,995
+99.1%
0.00%
+100.0%
Q3 2019$5,140,000
+2078.0%
967,963
+1472.5%
0.00%
Q2 2019$236,000
-47.2%
61,556
-29.6%
0.00%
Q1 2019$447,000
+342.6%
87,489
+65.7%
0.00%
Q4 2018$101,000
-92.1%
52,810
-84.4%
0.00%
Q3 2018$1,280,000
-10.6%
338,567
-26.2%
0.00%
Q2 2018$1,432,000
+37.3%
458,962
+5.1%
0.00%
Q1 2018$1,043,000
-27.2%
436,652
+19.2%
0.00%
Q4 2017$1,432,000
+1145.2%
366,378
+704.0%
0.00%
Q3 2017$115,000
+121.2%
45,568
+141.7%
0.00%
Q2 2017$52,000
+44.4%
18,852
+1.1%
0.00%
Q1 2017$36,000
-20.0%
18,654
-56.6%
0.00%
Q4 2016$45,000
-76.2%
42,979
-75.2%
0.00%
Q3 2016$189,000
+40.0%
173,400
-8.5%
0.00%
Q2 2016$135,000
+13.4%
189,607
+86.2%
0.00%
Q1 2016$119,000
+75.0%
101,855
+265.1%
0.00%
Q4 2015$68,000
+38.8%
27,897
+133.6%
0.00%
Q2 2015$49,000
-89.0%
11,942
-88.4%
0.00%
Q1 2015$446,000
+696.4%
102,924
+450.3%
0.00%
Q4 2014$56,000
+36.6%
18,702
+53.0%
0.00%
Q3 2014$41,00012,2200.00%
Other shareholders
CATALYST PHARMACEUTICALS INC shareholders Q4 2020
NameSharesValueWeighting ↓
TANAKA CAPITAL MANAGEMENT INC 208,189$1,726,0003.48%
FRIESS ASSOCIATES LLC 571,940$4,741,0002.53%
GABLES CAPITAL MANAGEMENT INC. 438,764$3,637,0002.28%
Prairiewood Capital, LLC 258,073$2,139,0001.50%
Quantedge Capital Pte Ltd 597,300$4,952,0001.46%
ARMISTICE CAPITAL, LLC 8,372,000$69,404,0001.34%
SummerHaven Investment Management, LLC 158,473$1,314,0000.74%
Capital Impact Advisors, LLC 99,322$823,0000.60%
EAM Investors, LLC 365,415$3,029,0000.56%
GLOBEFLEX CAPITAL L P 304,515$2,524,0000.51%
View complete list of CATALYST PHARMACEUTICALS INC shareholders